Savara Inc.
NASDAQ:SVRABiotechnology
+$0.03 today
- Market cap
- $1.04B
- Beta
- 0.27
- P/E (TTM)
- -10.6
- EPS (TTM)
- -$0.51
Volume 5.51M
Average 1.53M
SVRA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Savara Inc.NASDAQ: SVRA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $23.4M rose 22.1% year over year, ahead of the +6.5% change in trailing-twelve-month research & development. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +42.9% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +22.1% holds above the trailing-twelve-month pace of +6.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 81.4M USD
- Year-over-year change
- +4.3%
- 4-year CAGR
- +29.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.4M | +4.3% |
| FY2024 | 2024-12-31 | 78.03M | +76.3% |
| FY2023 | 2023-12-31 | 44.26M | +58.8% |
| FY2022 | 2022-12-31 | 27.88M | -3.8% |
| FY2021 | 2021-12-31 | 28.99M | — |
Research & Development vs competitors
How SVRA compares with its peers on the latest reported figures
- SVRA's LTM Mar 2026 research & development of $85.64M is the highest of the 2 companies compared; the peer median is $31.39M.
- Its year-over-year change of +6.5% is the highest of 2, against a peer median of -21.6%.
- Over three fiscal years its annual growth of +42.9% compares with a peer median of -18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.64M | +6.5% | +42.9% | — | |
| LTM Mar 2026 | $31.39M | -21.6% | -18.9% | 28.6% | |
APMDApnimed, Inc. | — | — | — | — | — |
| Peer median (excluding SVRA) | $31.39M | -21.6% | -18.9% | 28.6% | |
Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 28.99M | 27.88M | 44.26M | 78.03M | 245K |
| Gross Profit | (28.99M) | (27.88M) | (44.26M) | (78.03M) | (245K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 28.99M | 27.88M | 44.26M | 78.03M | 81.4M |
| Selling, General & Admin | 12.35M | 10.93M | 15.67M | 25.04M | 42.06M |
| Operating Expenses | 12.49M | 10.96M | 15.75M | 25.17M | 123.3M |
| Depreciation & Amortization | 136K | 31K | 77K | 130K | 245K |
| EBITDA | (40.5M) | (38.01M) | (59.13M) | (102.27M) | (118.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (41.48M) | (38.84M) | (60.01M) | (103.2M) | (123.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.28K | 88 | 4.44M | 6.47M | 4.16M |
| Interest Expense | 2.28M | 88K | 0 | 0 | 0 |
| Other Income / Expenses | (1.54M) | 689K | 5.31M | 7.32M | 4.71M |
| Income Before Tax | (43.01M) | (38.15M) | (54.7M) | (95.88M) | (118.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.01M) | (38.15M) | (54.7M) | (95.88M) | (118.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.32) | (0.25) | (0.33) | (0.48) | (0.53) |
| EPS (Diluted) | (0.32) | (0.25) | (0.33) | (0.48) | (0.53) |
| Weighted Avg Shares | 133.92M | 152.77M | 165.2M | 198.19M | 222.39M |
| Weighted Avg Shares (Diluted) | 133.92M | 152.77M | 165.2M | 198.19M | 222.39M |
Savara Inc.
NASDAQ:SVRA
Intrinsic Alpha fair value
Locked
Current Price
$4.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.